Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

Completed · Phase 3 · Has a placebo group

Conditions studied: Peanut Allergy

In brief

This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.

Key facts

Study ID
NCT03126227
Run by
Aimmune Therapeutics, Inc.
People needed
506
Starts
2017-05-08
Expected to finish
2018-09-23
Last updated by the study team
2021-11-02

Who can join

Age: 4 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.